Published in Virol J on October 02, 2006
Inhibition of transfer to secondary receptors by heparan sulfate-binding drug or antibody induces noninfectious uptake of human papillomavirus. J Virol (2007) 1.96
Target cell cyclophilins facilitate human papillomavirus type 16 infection. PLoS Pathog (2009) 1.57
Viral entry mechanisms: human papillomavirus and a long journey from extracellular matrix to the nucleus. FEBS J (2009) 1.36
Multiple heparan sulfate binding site engagements are required for the infectious entry of human papillomavirus type 16. J Virol (2013) 1.06
Multiscale simulation of microbe structure and dynamics. Prog Biophys Mol Biol (2011) 0.96
A cryo-electron microscopy study identifies the complete H16.V5 epitope and reveals global conformational changes initiated by binding of the neutralizing antibody fragment. J Virol (2014) 0.88
Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implications. Protein Sci (2009) 0.86
Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines. Infect Genet Evol (2013) 0.80
Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins. Hum Vaccin Immunother (2015) 0.79
Principles of polyoma- and papillomavirus uncoating. Med Microbiol Immunol (2012) 0.79
The cytoskeleton in papillomavirus infection. Viruses (2011) 0.78
The DE and FG loops of the HPV major capsid protein contribute to the epitopes of vaccine-induced cross-neutralising antibodies. Sci Rep (2016) 0.77
Naturally Occurring Major and Minor Capsid Protein Variants of Human Papillomavirus 45 (HPV45): Differential Recognition by Cross-Neutralizing Antibodies Generated by HPV Vaccines. J Virol (2015) 0.75
Human papillomavirus major capsid protein L1 remains associated with the incoming viral genome throughout the entry process. J Virol (2017) 0.75
Crystal Structures of Two Immune Complexes Identify Determinants for Viral Infectivity and Type-Specific Neutralization of Human Papillomavirus. MBio (2017) 0.75
The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res (1997) 175.36
Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene (1989) 60.30
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol (1999) 40.46
Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med (2003) 31.67
A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med (2002) 10.58
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol (2005) 9.67
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet (2004) 8.09
Product review. New mammalian expression vectors. Nature (1990) 7.97
Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A (1992) 7.72
Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol (1992) 7.14
Efficient intracellular assembly of papillomaviral vectors. J Virol (2004) 5.36
Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J Virol (1993) 4.00
Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology (2004) 3.85
In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J Virol (1996) 3.66
Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol (1993) 3.65
Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell (2000) 3.44
Human papillomavirus infection requires cell surface heparan sulfate. J Virol (2001) 3.32
Maturation of papillomavirus capsids. J Virol (2005) 3.18
Generation and neutralization of pseudovirions of human papillomavirus type 33. J Virol (1997) 2.29
Further evidence that papillomavirus capsids exist in two distinct conformations. J Virol (2003) 2.02
Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes. J Virol (2001) 2.02
Assembly of the major and the minor capsid protein of human papillomavirus type 33 into virus-like particles and tubular structures in insect cells. Virology (1994) 1.89
Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope. J Virol (1997) 1.66
Characterization of a major neutralizing epitope on human papillomavirus type 16 L1. J Virol (1999) 1.52
Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types. Virology (2001) 1.52
Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies. J Virol (1998) 1.49
Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6. Virology (1996) 1.45
Analysis of type-restricted and cross-reactive epitopes on virus-like particles of human papillomavirus type 33 and in infected tissues using monoclonal antibodies to the major capsid protein. J Gen Virol (1994) 1.44
Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol (2002) 1.35
DNA-induced structural changes in the papillomavirus capsid. J Virol (2001) 1.29
Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1. J Virol (2003) 1.27
A neutralizing epitope of human papillomavirus type 11 is principally described by a continuous set of residues which overlap a distinct linear, surface-exposed epitope. J Virol (1997) 1.20
Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera. J Virol (2006) 1.20
A rapid and efficient method for multiple-site mutagenesis with a modified overlap extension PCR. Appl Microbiol Biotechnol (2005) 1.16
Heparan sulfate proteoglycans interact exclusively with conformationally intact HPV L1 assemblies: basis for a virus-like particle ELISA. J Med Virol (2005) 1.15
Identification of type-specific and cross-reactive neutralizing conformational epitopes on the major capsid protein of human papillomavirus type 31. Arch Virol (2006) 1.02
A novel human papillomavirus type 6 neutralizing domain comprising two discrete regions of the major capsid protein L1. Virology (2001) 1.00
Humoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 l1 capsomers. J Virol (2005) 0.98
Highly efficient transport of carboxyfluorescein diacetate succinimidyl ester into COS7 cells using human papillomavirus-like particles. FEBS Lett (2003) 0.89
Pseudovirions as specific tools for investigation of virus interactions with cells. Methods Mol Biol (2005) 0.78
A membrane-destabilizing peptide in capsid protein L2 is required for egress of papillomavirus genomes from endosomes. J Virol (2006) 2.16
Analysis of the infectious entry pathway of human papillomavirus type 33 pseudovirions. Virology (2002) 2.04
Further evidence that papillomavirus capsids exist in two distinct conformations. J Virol (2003) 2.02
Inhibition of transfer to secondary receptors by heparan sulfate-binding drug or antibody induces noninfectious uptake of human papillomavirus. J Virol (2007) 1.96
Surface-exposed amino acid residues of HPV16 L1 protein mediating interaction with cell surface heparan sulfate. J Biol Chem (2007) 1.66
Clathrin- and caveolin-independent entry of human papillomavirus type 16--involvement of tetraspanin-enriched microdomains (TEMs). PLoS One (2008) 1.63
Target cell cyclophilins facilitate human papillomavirus type 16 infection. PLoS Pathog (2009) 1.57
Identification of a dynein interacting domain in the papillomavirus minor capsid protein l2. J Virol (2006) 1.53
Reorganization of nuclear domain 10 induced by papillomavirus capsid protein l2. Virology (2002) 1.36
Cyclophilins facilitate dissociation of the human papillomavirus type 16 capsid protein L1 from the L2/DNA complex following virus entry. J Virol (2012) 1.34
Nuclear translocation of papillomavirus minor capsid protein L2 requires Hsc70. J Virol (2004) 1.27
Assembly and translocation of papillomavirus capsid proteins. J Virol (2002) 1.26
Heparan sulfate proteoglycans interact exclusively with conformationally intact HPV L1 assemblies: basis for a virus-like particle ELISA. J Med Virol (2005) 1.15
Dissection of human papillomavirus type 33 L2 domains involved in nuclear domains (ND) 10 homing and reorganization. Virology (2003) 1.14
Structural basis of oligosaccharide receptor recognition by human papillomavirus. J Biol Chem (2010) 1.13
Nuclear localization but not PML protein is required for incorporation of the papillomavirus minor capsid protein L2 into virus-like particles. J Virol (2004) 1.08
Multiple heparan sulfate binding site engagements are required for the infectious entry of human papillomavirus type 16. J Virol (2013) 1.06
Human papillomavirus types 16, 18, and 31 share similar endocytic requirements for entry. J Virol (2013) 1.01
DNA binding of L1 is required for human papillomavirus morphogenesis in vivo. Virology (2002) 0.96
Heparin-based ELISA reduces background reactivity in virus-like particle-based papillomavirus serology. J Gen Virol (2005) 0.94
Host-cell factors involved in papillomavirus entry. Med Microbiol Immunol (2012) 0.92
Highly efficient transport of carboxyfluorescein diacetate succinimidyl ester into COS7 cells using human papillomavirus-like particles. FEBS Lett (2003) 0.89
Plasmid-based generation of recombinant coxsackievirus B3 particles carrying capsid gene replacement replicons. Virus Res (2004) 0.80
Combination of crossflow ultrafiltration, monolithic affinity filtration, and quantitative reverse transcriptase PCR for rapid concentration and quantification of model viruses in water. Environ Sci Technol (2012) 0.79
Monitoring of adenovirus serotypes in environmental samples by combined PCR and melting point analyses. Virol J (2013) 0.78
Pseudovirions as specific tools for investigation of virus interactions with cells. Methods Mol Biol (2005) 0.78
The cytoskeleton in papillomavirus infection. Viruses (2011) 0.78
Binding of human papillomavirus type 16 to heparan sulfate is inhibited by mucosal antibodies from patients with low-grade squamous intraepithelial lesions but not from cervical cancer patients. FEMS Immunol Med Microbiol (2008) 0.76
Generation and applications of HPV pseudovirions using vaccinia virus. Methods Mol Med (2005) 0.75